Overall, the prospect of bone regeneration by small molecules seems to be focused on the role that Smad activators and Smurf1 inhibitors play in the process, which is partly similar to the course of studies in Parkinson's disease therapeutics. Here, SMURF1 is linked to Parkinson disease.